TRAP1 and benign prostatic hyperplasia: This is consistent with the abundant distribution of one of the targets of Gamitrinibs (Kang et al, 2007), the mitochondrial Hsp90 homologue TNF receptor-associated protein-1 (Trepel et al, 2010), in all Gleason grade localised and metastatic prostate cancer in humans, but not benign prostatic hyperplasia (Leav et al, 2010).